市場調查報告書
商品編碼
1503397
至 2030 年微創手術市場預測:按產品類型、應用、最終用戶和地區分類的全球分析Minimally Invasive Surgery Market Forecasts to 2030 - Global Analysis By Product Type, Application, End User and By Geography |
根據 Stratistics MRC 的數據,2024 年全球微創手術市場規模達 819 億美元,預計預測期內複合年成長率為 13.0%,到 2030 年將達到 1,705 億美元。
微創手術利用腹腔鏡和機器人系統等先進技術,透過小切口進行手術操作,減少對身體的創傷。與傳統的開放性手術相比,這種方法可以實現更快的恢復時間、更少的疼痛、更少的疤痕以及更低的併發症。技術進步、患者對微創手術的偏好增加以及 MIS 技術在各個醫療領域的不斷擴大應用正在推動成長。
據歐洲心臟學會 (ESC) 稱,與傳統的心臟直視手術相比,經導管主動脈瓣置換術(TAVR) 等微創心血管手術由於風險更低、恢復時間更快而變得越來越受歡迎。
慢性病增加
心血管疾病、癌症和糖尿病等慢性疾病的盛行率不斷上升,推動了對微創手術的需求。這些手術恢復時間更快,感染風險更低,術後疼痛更少,使其成為患者和醫療保健提供者的首選。隨著世界人口老化和慢性病的增加,對微創手術技術的需求預計將大幅成長。
設備和流程高成本
機器人輔助手術系統和高清成像設備等先進技術價格昂貴,對於小型醫療機構和低收入地區的患者來說難以取得。這些成本可能會限制微創技術的採用,特別是在醫療保健預算有限的新興國家。
加大醫療保健投資
增加對醫療基礎設施和技術進步的投資是微創手術市場的重大機會。政府和私人組織正在增加對醫療保健計劃的資助,例如先進手術器械的開發和醫療專業人員的培訓計劃。這些投資預計將提高微創手術的可及性和效率,並推動市場成長。
併發症的風險
儘管微創手術有好處,但也存在風險,包括麻醉併發症、感染疾病和周圍組織的意外併發症。這些潛在的併發症可能會阻止患者和醫療保健提供者選擇微創技術。此外,執行這些程序需要專門的培訓和專業知識,這可能會限制採用並對市場成長構成威脅。
COVID-19的爆發對微創手術市場產生了重大影響。為了優先考慮 COVID-19 患者,選擇性手術被推遲或取消,導致需求暫時下降。然而,這場大流行也凸顯了微創手術對於縮短住院時間和盡量減少病患感染疾病的重要性。
腹腔鏡設備領域預計將在預測期內成為最大的領域
腹腔鏡器械細分市場預計將在預測期內創下最大的市場佔有率,因為它廣泛應用於胃腸道、婦科和泌尿系統等各種外科手術。這些器械具有精確性、縮短恢復時間和最小化疤痕,使其深受外科醫生和患者的歡迎。腹腔鏡技術的不斷進步和腹腔鏡手術的增加正在推動該領域的成長。
預計門診手術中心產業在預測期內複合年成長率最高
門診手術中心(ASC)領域預計在預測期內複合年成長率最高。 ASC 為傳統的醫院手術提供了一種經濟高效且方便的替代方案,從而縮短了手術時間並加快了患者康復速度。對門診手術的日益偏好和微創技術的進步正在推動 ASC 的快速成長。此外,ASC的增加和有利的報銷政策也有助於該行業的擴張。
由於其先進的醫療基礎設施、創新手術技術的高採用率以及主要市場參與者的存在,北美在微創手術市場佔據主導地位。該地區完善的醫療保健體系和對研發的大量投資使其在市場上佔有最大佔有率。此外,慢性病的高盛行率和微創手術需求的增加也推動了北美市場的成長。
由於醫療保健支出的增加、微創手術意識的增強以及醫療基礎設施的改善,亞太地區的微創手術市場預計將快速成長。中國、印度和日本等國家正在大力投資醫療保健和技術進步,預計將推動微創手術的採用。醫療旅遊業的成長和慢性病的流行也促進了該地區的高複合年成長率。
According to Stratistics MRC, the Global Minimally Invasive Surgery Market is accounted for $81.9 billion in 2024 and is expected to reach $170.5 billion by 2030 growing at a CAGR of 13.0% during the forecast period. Minimally Invasive Surgery involves performing surgical procedures through small incisions, utilizing advanced technologies like laparoscopes and robotic systems, to reduce trauma to the body. This approach leads to shorter recovery times, less pain, reduced scarring, and a lower risk of complications compared to traditional open surgery. The growth is driven by technological advancements, increasing patient preference for less invasive procedures, and the expanding applications of MIS techniques across various medical fields, resulting in their widespread adoption and development.
According to the European Society of Cardiology (ESC), minimally invasive cardiac surgeries, such as transcatheter aortic valve replacement (TAVR), have become increasingly popular due to their lower risk and shorter recovery times compared to traditional open-heart surgeries.
Increasing prevalence of chronic diseases
The rising incidence of chronic diseases such as cardiovascular disorders, cancer, and diabetes is driving the demand for minimally invasive surgeries. These procedures offer reduced recovery times, lower risk of infection, and less postoperative pain, making them a preferred choice for both patients and healthcare providers. As the global population ages and the prevalence of chronic conditions increases, the demand for minimally invasive surgical techniques is expected to grow significantly.
High cost of equipment and procedures
Advanced technologies such as robotic-assisted surgery systems and high-definition imaging devices are expensive, making them less accessible to smaller healthcare facilities and patients in low-income regions. These costs can limit the adoption of minimally invasive techniques, particularly in developing countries where healthcare budgets are constrained.
Increasing investment in healthcare
Growing investments in healthcare infrastructure and technological advancements present significant opportunities for the minimally invasive surgery market. Governments and private entities are increasingly funding healthcare projects, including the development of advanced surgical tools and training programs for medical professionals. These investments are expected to enhance the accessibility and efficiency of minimally invasive procedures, driving market growth.
Risk of complications
Despite the benefits, minimally invasive surgeries carry risks such as complications from anesthesia, infections, and accidental damage to surrounding tissues. These potential complications can deter patients and healthcare providers from opting for minimally invasive techniques. Additionally, the need for specialized training and expertise to perform these procedures can limit their widespread adoption, posing a threat to market growth.
The COVID-19 pandemic significantly impacted the minimally invasive surgery market. Elective surgeries were postponed or canceled to prioritize Covid-19 patients, leading to a temporary decline in demand. However, the pandemic also highlighted the importance of minimally invasive techniques in reducing hospital stays and minimizing patient exposure to infections, which is expected to drive long-term growth in the market.
The laparoscopic instruments segment is expected to be the largest during the forecast period
The laparoscopic instruments segment is expected to register largest market share during the forecast period due to their widespread use in various surgical procedures, including gastrointestinal, gynecological, and urological surgeries. These instruments offer precision, reduced recovery times, and minimal scarring, making them highly popular among surgeons and patients. The continuous advancements in laparoscopic technology and the increasing number of laparoscopic procedures are driving the growth of this segment.
The ambulatory surgical centers segment is expected to have the highest CAGR during the forecast period
The ambulatory surgical centers (ASCs) segment is expected to have the highest CAGR during the forecast period. ASCs offer cost-effective and convenient alternatives to traditional hospital-based surgeries, with shorter procedure times and faster patient recovery. The growing preference for outpatient surgeries, coupled with advancements in minimally invasive techniques, is driving the rapid growth of ASCs. Additionally, the increasing number of ASCs and favorable reimbursement policies are contributing to the segment's expansion.
North America is positioned to dominate the minimally invasive surgery market due to its advanced healthcare infrastructure, high adoption of innovative surgical technologies, and the presence of key market players. The region's well-established healthcare system and significant investments in research and development contribute to its leading market share. Additionally, the high prevalence of chronic diseases and the increasing demand for minimally invasive procedures further drive market growth in North America.
The Asia Pacific region anticipates rapid growth in the minimally invasive surgery market, driven by the increasing healthcare expenditure, rising awareness about minimally invasive techniques, and improving healthcare infrastructure. Countries like China, India, and Japan are witnessing significant investments in healthcare and technological advancements, which are expected to boost the adoption of minimally invasive surgeries. The growing medical tourism industry and the increasing prevalence of chronic diseases also contribute to the region's high CAGR.
Key players in the market
Some of the key players in Minimally Invasive Surgery Market include Medtronic plc, Johnson & Johnson (Ethicon), Stryker Corporation, Boston Scientific Corporation, Olympus Corporation, Smith & Nephew plc, Zimmer Biomet Holdings, Inc., Intuitive Surgical, Inc., Abbott Laboratories, B. Braun Melsungen AG, ConMed Corporation, Karl Storz SE & Co. KG, Cook Medical, Applied Medical Resources Corporation, Richard Wolf GmbH, FUJIFILM Holdings Corporation, HOYA Corporation, Teleflex Incorporated, Arthrex, Inc. and NuVasive, Inc.
In March 2023, Medtronic received FDA clearance for its Steerable Flex Robotic Clip Applier used with the Hugo system for minimally invasive gynecologic procedures.
In January 2023, Ethicon launched the ECHELON+ Stapler for minimally invasive colorectal, gastric, and thoracic surgeries.
In January 2023, Boston Scientific received FDA approval for its EXALT Model D Single-Use Duodenoscope for minimally invasive endoscopic procedures.
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.